What is the official website of Apotek 1 ?

The official website of Apotek 1 is https://www.apotek1.no.

What is Apotek 1's cybersecurity risk score?

Apotek 1 has an AI-generated cybersecurity risk score of 760 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Apotek 1 experienced?

According to Rankiteo, Apotek 1 currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Apotek 1 been affected by any supply chain cyber incidents ?

According to Rankiteo, Apotek 1 has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Apotek 1 have SOC 2 Type 1 certification ?

According to Rankiteo, Apotek 1 is not certified under SOC 2 Type 1.

Does Apotek 1 have SOC 2 Type 2 certification ?

According to Rankiteo, Apotek 1 does not hold a SOC 2 Type 2 certification.

Does Apotek 1 comply with GDPR ?

According to Rankiteo, Apotek 1 is not listed as GDPR compliant.

Does Apotek 1 have PCI DSS certification ?

According to Rankiteo, Apotek 1 does not currently maintain PCI DSS compliance.

Does Apotek 1 comply with HIPAA ?

According to Rankiteo, Apotek 1 is not compliant with HIPAA regulations.

Does Apotek 1 have ISO 27001 certification ?

According to Rankiteo,Apotek 1 is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Apotek 1 operate in ?

Apotek 1 operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Apotek 1 have ?

Apotek 1 employs approximately 2,566 people worldwide.

Does Apotek 1 own any subsidiaries ?

Apotek 1 presently has no subsidiaries across any sectors.

How many LinkedIn followers does Apotek 1 have ?

Apotek 1's official LinkedIn profile has approximately 13,177 followers.

What is the NAICS classification code for Apotek 1 ?

Apotek 1 is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Apotek 1 have a Crunchbase profile ?

No, Apotek 1 does not have a profile on Crunchbase.

Does Apotek 1 have a LinkedIn profile ?

Yes, Apotek 1 maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/apotek1.

How many cybersecurity incidents has Apotek 1 experienced ?

As of June 20, 2026, Rankiteo reports that Apotek 1 has not experienced any cybersecurity incidents.

How many peer or competitor companies does Apotek 1 have ?

Apotek 1 has an estimated 5,693 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Apotek 1

Boost Score +25 with badge (5 left)

760

/1000

Fair

785

/1000

Fair

Apotek 1 Vendor Cyber Rating & Cyber Score

apotek1.no

Add Your Compliance Badge

Apotek 1 er Norges største apotekkjede - også på nett. På hvert av våre apotek er vår ambisjon å være best for våre kunder. Apotek 1 er Norges største apotekkjede med en markedsandel på over 50 prosent. Hos oss jobber 4500 dedikerte medarbeidere. Med over 460 apotek fordelt på alle landets fylker og tre grossistlagre er vi godt posisjonert til å fortsette veksten og å tilby vår service og kompetanse til nye kunder og kundegrupper i hele vårt langstrakte land. Våre medarbeidere selger alle typer reseptbelagte og reseptfrie legemidler, og vi tilbyr også et bredt utvalg av kvalitetsikrede helse- og velværeprodukter til konkurransedyktige priser. Samtidig gir vi god veiledning til våre kunder.

Apotek 1 A.I CyberSecurity Scoring

Scoring History

Apotek 1

Apotek 1 CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Apotek 1 Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Apotek 1

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Apotek 1 in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Apotek 1 in 2026.

Incident Types Apotek 1 vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Apotek 1 in 2026.

Incident History - Apotek 1 (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Apotek 1 Subsidiaries

Apotek 1

Pharmaceutical Manufacturing

Website: https://www.apotek1.no

Company Size: 1,001-5,000 employees

PHOENIX group - Integrated Healthcare ProviderWholesale

BENU FarmaciaPharmaceutical Manufacturing

PHOENIX Pharma BulgariaPharmaceutical Manufacturing

PHOENIX Pharmahandel GmbH & Co KGWholesale

Help Net FarmaPharmaceutical Manufacturing

BENU BelgiumPharmaceutical Manufacturing

Pharmacies BENU SAPharmaceutical Manufacturing

NomecoTransportation, Logistics, Supply Chain and Storage

Gruppo ComifarTransportation, Logistics, Supply Chain and Storage

PHX IrelandPharmaceutical Manufacturing

SOFIADISWholesale

PHOENIX Medical Supplies LtdPharmaceutical Manufacturing

EL PHARMA – PHOENIX group Representation ServicesHealth and Human Services

PHOENIX FarmacijaPharmaceutical Manufacturing

PHOENIX BelgiumHospitals and Health Care

PHOENIX Pharma ItaliaWholesale

PHOENIX Pharma Switzerland AGHealth and Human Services

BENU SlovenskoPharmaceutical Manufacturing

Tamro FinlandWholesale

Tamro BalticsPharmaceutical Manufacturing

Tamro SwedenPharmaceutical Manufacturing

SmilaHospitals and Health Care

Kemofarmacija d.d.Wholesale

OCP PortugalWholesale

PHOENIX Zdravotnícke zásobovanie, a.s.Wholesale

FarmeximWholesale Drugs and Sundries

Loading…

Apotek 1 Similar Companies

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Loading…

NEWS

Apotek 1 CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56082

SUMMARY

Capgo (Cap-go/capgo) before 12.128.2 contains an improper access control vulnerability in the SECURITY DEFINER PostgREST RPC function public.record_build_time, which is granted to the anon role and callable with only the public Supabase publishable (sb_publishable_*) anon key. An unauthenticated attacker can insert rows into public.build_logs for arbitrary organizations and, because the function uses ON CONFLICT (build_id, org_id) DO UPDATE, can overwrite existing usage/billing records by reusing the same build_id for a target org. This enables cross-tenant tampering of billing build logs and financial-impact denial of service by inflating billable build time.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:N

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56081

SUMMARY

Cap-go before 12.128.2 contains an authentication logic flaw that lets an attacker register and control an account bound to a victim's email address before that email is verified. By enabling two-factor authentication on the pre-registered account, the attacker gains control over the account claimed under the victim's identity, allowing them to read and modify its state and enforce organization-level policies, while the legitimate user is denied access to the account tied to their own email.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

3.9

REFERENCES

CVE-2026-56080

SUMMARY

Capgo before 12.128.2 contains a flaw in the Enforce Password Policy feature: after a Super Admin enables the policy and successfully changes their password to a compliant one, the backend does not update the password-compliance state. As a result, the backend continues to treat the account as non-compliant and repeatedly forces password-reset prompts, permanently locking the Super Admin out of organization access (organization lockout / denial of service) despite valid authentication.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 4.9)

cvss3

Base Score: 4.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

1.2

REFERENCES

CVE-2026-56079

SUMMARY

Capgo before 12.128.2 contains a cross-tenant authorization bypass vulnerability in PostgREST endpoints that allows org-scoped read API keys to access other tenants' webhook secrets and delivery logs. Attackers can query the webhooks and webhook_deliveries endpoints to exfiltrate HMAC signing secrets and delivery payloads, enabling forged webhook events against victim organizations.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-56073

SUMMARY

Cap-go before 12.128.2 contains an authentication bypass vulnerability in OTP verification that allows attackers to bypass email verification by modifying server responses. Attackers can intercept OTP verification requests and manipulate HTTP responses to falsely mark verification successful, enabling unauthorized 2FA enablement and account takeover.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 9.4)

cvss3

Base Score: 9.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:L

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.5

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…